Success Metrics

Clinical Success Rate
85.7%

Based on 6 completed trials

Completion Rate
86%(6/7)
Active Trials
0(0%)
Results Posted
117%(7 trials)
Terminated
1(14%)

Phase Distribution

Ph phase_2
4
57%
Ph phase_3
3
43%

Phase Distribution

0

Early Stage

4

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
4(57.1%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(6)
Terminated(1)

Detailed Status

Completed6
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
85.7%
Most Advanced
Phase 3

Trials by Phase

Phase 24 (57.1%)
Phase 33 (42.9%)

Trials by Status

terminated114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

NCT00532155
terminatedphase_3

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

NCT00574275
completedphase_2

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

NCT00327171
completedphase_2

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

NCT00396591
completedphase_2

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

NCT00327444
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT00532155Phase 3

A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Completed
NCT00574275Phase 3

Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer

Terminated
NCT00327171Phase 2

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

Completed
NCT00396591Phase 2

AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites

Completed
NCT00327444Phase 2

Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites

Completed
NCT00284141Phase 2

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Completed
NCT00561470Phase 3

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7